Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
11C-BMS-986196 PET Ligand Safety and Kinetics in Healthy and MS Participants
NCT05064436Phase 1Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 1, open-label trial of 11c-bms-986196 in multiple sclerosis (MS) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events Based on Severity, Number of Participants With Clinically Significant Changes in Electrocardiograms and 10 more. Started Dec 2021; status: terminated.
02
Drugs
11c-bms-986196
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05064436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05064436.